These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19149503)

  • 21. Efficacy and safety of aztreonam-clindamycin versus tobramycin-clindamycin in the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli.
    Rodríguez JR; Ramírez-Ronda CH; Nevárez M
    Antimicrob Agents Chemother; 1985 Feb; 27(2):246-51. PubMed ID: 4039118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective randomized trial of ceftazidime versus cefazolin/tobramycin in the treatment of hospitalized patients with pneumonia.
    Mandell LA; Nicolle LE; Ronald AR; Landis SJ; Duperval R; Harding GK; Robson HG; Feld R; Vincelette J; Fong I
    J Antimicrob Chemother; 1987 Jul; 20(1):95-107. PubMed ID: 3305464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections.
    Huang CK; Chen YS; Lee SS; Lin WR; Tsai HC; Lin HH; Wann SR; Chen JY; Yen MY; Liu YC
    J Microbiol Immunol Infect; 2002 Sep; 35(3):159-67. PubMed ID: 12380788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftazidime, a new cephalosporin in the treatment of complicated urinary tract infections: a comparative study with tobramycin.
    Frimodt-Møller PC; Madsen PO
    J Urol; 1983 Oct; 130(4):796-7. PubMed ID: 6350625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative clinical efficacy and safety of netilmicin and tobramycin in children with serious gram-negative infections.
    Weippl G
    Clin Ther; 1983; 5(4):342-7. PubMed ID: 6347380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections.
    Gallis HA; Brennan RO; Goodwin SD; Swinney V; Rumbaugh MM; Drew RH
    Am J Med; 1989 Nov; 87(5A):176S-180S. PubMed ID: 2686418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tobramycin--clinical pharmacology and chemotherapy].
    Periti P
    J Chemother; 1996 Jan; 8 Suppl 1():3-30. PubMed ID: 8948764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients.
    Fainstein V; Bodey GP; Elting L; Bolivar R; Keating MJ; McCredie KB; Valdivieso M
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():101-10. PubMed ID: 6352612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evaluation of tobramycin in respiratory and systemic infections in immunodepressed and normal patients.
    Altucci P; Abbate GF; Alagia I; Leonessa V
    J Infect Dis; 1976 Aug; 134 Suppl():S182-6. PubMed ID: 972280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ceftazidime in common infections in childhood. Experience in 262 cases].
    Fanos V; Fostini R; Panebianco R; Danieli D
    Clin Ter; 1991 Jun; 137(5):327-32. PubMed ID: 1832605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceftazidime versus ceftazidime plus tobramycin in febrile neutropenic children.
    Jacobs RF; Vats TS; Pappa KA; Chaudhary S; Kletzel M; Becton DL
    Infection; 1993; 21(4):223-8. PubMed ID: 8225625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical evaluation of combined therapy of ceftazidime and tobramycin for intractable pulmonary infection mainly caused by Pseudomonas aeruginosa].
    Kikuchi N; Kawashima T; Igari H; Kuriyama T; Kohno N; Onozaki I; Muraki N; Miyazaki RM; Kanno H; Ishiyama N
    Jpn J Antibiot; 1992 Jul; 45(7):799-808. PubMed ID: 1522670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience in the treatment of lower respiratory tract infections with ceftazidime.
    Pettersson T; Ahvonen P; Storgårds E
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():303-5. PubMed ID: 19803003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of ceftazidime in severe Gram-negative infections--a preliminary study.
    Clumeck N; Vanlaethem Y; Gordts B; Jaspar N; Butzler JP
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():317-21. PubMed ID: 19803007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
    Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM
    Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis.
    Permin H; Koch C; Høiby N; Christensen HO; Møller AF; Møller S
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():313-23. PubMed ID: 6352636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with ceftazidime for lower respiratory tract infections.
    De Sandre G; Corrocher RI; Gabrielli GB; Ho I
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():307-10. PubMed ID: 19803004
    [No Abstract]   [Full Text] [Related]  

  • 38. Cefepime versus ceftazidime in the treatment of lower respiratory tract infections.
    Aufiero A; Sturani C; Zanon P; Marruchella A; Michetti G; Nicolin E; Sella D; Goglio A; Silleni M; La Regina A
    J Chemother; 1997 Jun; 9(3):213-8. PubMed ID: 9210005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group.
    Richard DA; Nousia-Arvanitakis S; Sollich V; Hampel BJ; Sommerauer B; Schaad UB
    Pediatr Infect Dis J; 1997 Jun; 16(6):572-8. PubMed ID: 9194107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients.
    Miller JA; Butler T; Beveridge RA; Kales AN; Binder RA; Smith LJ; Ueno WM; Milkovich G; Goldwater S; Marion A
    Clin Ther; 1993; 15(3):486-99. PubMed ID: 8364941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.